Search Within

Sheng Feng Cai

Formats
  1. Journal Article (26)
  2. Meeting Abstract (20)
  3. Review (3)
  4. Editorial (2)
  5. Research Letter (1)
Groups
  1. Adult Leukemia (52)
  2. Center for Hematologic Malignancies (52)
  3. Department of Medicine (52)
  4. Hematologic Malignancies, Division of (52)
  5. Hematology-Oncology Fellows (52)
  6. GSK Faculty (36)

More Groups

People
  1. Ross Levine (34)
  2. Eytan Stein (22)
  3. Christopher Famulare (19)
  4. Martin Tallman (19)
  5. Aaron Goldberg (17)
  6. Wenbin Xiao (17)

More People

Years
  1. 2025 (6)
  2. 2024 (8)
  3. 2023 (10)
  4. 2022 (4)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Blood (20)
  2. Blood Advances (5)
  3. Cancer Discovery (4)
  4. American Journal of Hematology (2)
  5. Cancer Cell (2)
  6. Nature (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. American Association for Cancer Research (6)
  3. Cell Press (5)
  4. Elsevier Inc. (2)
  5. John Wiley & Sons, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (52)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
    Research Letter

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Arcila, M.; Roshal, M.; Zhang, Y.; Famulare, C. A.; Goldberg, A. D.; Cai, S. F.; Dunbar, A.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
    Journal Article

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Daniyan, A. F.; Famulare, C.; Cuello, B. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
    Journal Article

    Xiao, W.; Miles, L. A.; Bowman, R. L.; Durani, V.; Tian, H. S.; DelGaudio, N. L.; Mishra, T.; Zhu, M.; Zhang, Y.; Stump, S. E.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
    Journal Article

    Cai, S. F.; Chu, S. H.; Goldberg, A. D.; Parvin, S.; Koche, R. P.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
    Journal Article

    Stanchina, M.; McKinnell, Z.; Park, J. H.; Stein, E. M.; Cai, S. F.; Taylor, J.
    Leukemia Research Reports (2020)

    Fulltext@MSK | Save
  • A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
    Meeting Abstract

    Menghrajani, K.; Cai, S. F.; Devlin, S. M.; Armstrong, S. A.; Piekarz, R.; Rudek, M.; Tallman, M. S.; Stein, E. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences p53 activity and therapeutic sensitivity via an Evi1-dependent mechanism
    Meeting Abstract

    Cai, S. F.; Chu, S.; Goldberg, A. D.; Parvin, S.; Koche, R.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save